Apexigen (NASDAQ: APGN), which recently combined with Brookline Capital in July 2022, announced that it will be acquired by Pyxis Oncology (NASDAQ:PYXS) in an all-stock transaction that would value it at $0.64 per share.
For each share of Apexigen, Pyxis Oncology will issue 0.1725 shares of its common stock for a total enterprise value of approximately $16 million.
Under the terms of the agreement, Pyxis Oncology expects to issue approximately 4.4 million shares of its common stock to Apexigen stockholders to acquire the company. Current stockholders of Pyxis Oncology will own approximately 90% of the combined company and Apexigen’s stockholders are expected to own 10%.
Pyxis Oncology last closed at $3.34 and so the price represents a 10.4% premium over Apexigen’s last closing price of $0.58.
Apexigen and Brookline Capital originally intended to raise $73 million through the merger, but were only able to generate $19 million in gross proceeds. After just six months of being a public company, Apexigen announced that it was evaluating strategic alternatives and implementing a corporate restructuring to extend its cash runway, which resulted in laying off 55% of its team.
With a shared vision of bringing innovative solutions to oncology patients, Pyxis expects to complete the all-stock transaction with Apexigen by mid-2023. Upon closing of the transaction, the combined company will trade on Nasdaq under the ticker symbol “PYXS” and the existing Pyxis Oncology leadership team will continue to be responsible for all executive positions.
Pyxis Oncology, Inc. is a clinical-stage company focused on defeating difficult-to-treat cancers and is building next-generation therapeutics that hold the potential for mono and combination therapies.
Latest SPAC Liquidations: Schultze Special Purpose Acquisition Corp. II Schultze Special Purpose Acquisition Corp. II (SAMA) to Liquidate on October 11, 2023 Schultze Special Purpose Acquisition Corp. II (Nasdaq: SAMA), announced that it will redeem all of the outstanding shares of its Class A common stock effective as of October 11, 2023. The Company expects...
Mercato Partners Acquisition Corporation (NASDAQ:MPRA) announced this afternoon via 8-K that its shareholders have approved its combination with Nuvini at a special meeting held earlier today. With 79.74% of the voting power of the Common Stock participating in the vote, the combination was overwhelmingly approved. 7,975,698 shares were recorded voting for the transaction, while only 38,008...
Home Plate Acquisition Corporation (NASDAQ:HPLT) announced that it adjourned this morning’s extension vote without conducting any business and it will pick things up again at 11 am ET October 2. Shareholders at the meeting are to consider giving Home Plate an extra two and half months to complete a deal, moving its deadline from October...
Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. Law firm Schulte sues SPAC over fees from failed Philippine casino merger U.S. law firm Schulte Roth & Zabel is suing its former client 26 Capital Acquisition Corp to recover more than $1.9 million in legal fees...
Fortune Rise Acquisition Corp. (NASDAQ:FRLA) announced this morning that it has changed the target of its letter of intent to combine, but only partially. The SPAC had an existing LOI to merge with its own sponsor, but since that sponsor is now a subsidiary of another company it has to combine with a different version...